Therapeutic subgroup
N06 – PSYCHOANALEPTIKA
- Anatomical main group N: NERVENSYSTEM
9Decisions
15Patient groups
Added benefit by patient group
- Considerable1
- Minor1
- Not proven13
Subgroups
- N06A ANTIDEPRESSIVA 3 decisions
- N06B PSYCHOSTIMULANZIEN, MITTEL ZUR BEHANDLUNG DER ADHS UND NOOTROPIKA 4 decisions
- N06D ANTIDEMENTIVA 2 decisions
Decisions, newest first
- 2026-04-16KisunlaDonanemabNot proven: 2 of 2 patient groups
- 2026-02-19LeqembiLecanemabNot proven: 2 of 2 patient groups
- 2023-09-21SpravatoEsketaminConsiderable
- 2022-03-18SunosiSolriamfetolNot proven
- 2021-08-19SpravatoEsketaminMinor
- 2020-11-05SunosiSolriamfetolNot proven: 2 of 2 patient groups
- 2019-10-17Elvanse AdultLisdexamfetamindimesilatNot proven: 2 of 2 patient groups
- 2015-10-15BrintellixVortioxetinNot proven: 3 of 3 patient groups
- 2013-11-14ElvanseLisdexamfetamindimesilatNot proven
Data status: 2026-10-29